Ensign Peak Advisors
NGM

Ensign Peak Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Ensign Peak Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,260
Closed -$43K – 2286
2022
Q3 		$43K Hold
3,260
– – ﹤0.01% 2240
2022
Q2 		$42K Hold
3,260
– – ﹤0.01% 2084
2022
Q1 		$50K Hold
3,260
– – ﹤0.01% 2131
2021
Q4 		$58K Buy
+3,260
New +$62.5K ﹤0.01% 2130

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ensign Peak Advisors's NGM Position: Q4 2022 in Review

Ensign Peak Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 3,260 shares — an estimated $43K sold.

Ensign Peak Advisors first reported a position in NGM in Q4 2021 and held it in 4 quarters. The position peaked at $58K in Q4 2021. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Ensign Peak Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 3,260 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $43K.
  • Ensign Peak Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $58K in Q4 2021.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.